Xi Tao Wang

Title: The Innovative Contributions of Xi Tao Wang

Introduction

Xi Tao Wang is a notable inventor based in Wellesley, MA (US). He has made significant contributions to the field of immunotherapy, particularly in the development of antibodies that target the PD-L1 protein. His work is crucial in advancing cancer treatment options.

Latest Patents

Xi Tao Wang holds a patent for "Antibodies that bind PD-L1 and uses thereof." This patent describes a method for immunotherapy aimed at subjects afflicted with cancer. The method involves administering a composition that includes a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 pathway. Additionally, the patent outlines a process for selecting suitable candidates for immunotherapy based on the expression levels of PD-L1 in tissue samples. The invention also includes rabbit monoclonal antibodies that specifically bind to PD-L1 antigens in formalin-fixed, paraffin-embedded (FFPE) tissue samples, along with an automated immunohistochemistry method for assessing cell surface expression.

Career Highlights

Xi Tao Wang is currently employed at Bristol-Myers Squibb Company, where he continues to work on innovative solutions in the field of cancer treatment. His research and development efforts are instrumental in creating effective therapies for patients.

Collaborations

Xi Tao Wang collaborates with several esteemed colleagues, including John P. Cogswell and Stacie M. Goldberg. Their combined expertise contributes to the advancement of immunotherapy research and development.

Conclusion

In summary, Xi Tao Wang is a pioneering inventor whose work in immunotherapy is making a significant impact in the fight against cancer. His innovative approaches and collaborations are paving the way for new treatment options that could benefit many patients in the future.